SCHEMBL144466

SCHEMBL144466

COC(=O)c1cc(-c2ccc(OC)cc2)nc2c1[nH]c1nc(OC)ccc12

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.82
PLA2G2A P14555 7/20 0.54
KLK7 P49862 1/20 0.50
KDM4E B2RXH2 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 5/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
ALPL P05186 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 3/20 0.41
ALDH1A1 P00352 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143932 0.91 JAK2 (0.82) JAK2PLA2G2AKLK7KDM4EMAPT
SCHEMBL142279 0.90 JAK2 (1.00) JAK2PLA2G2AKLK7KDM4ENPC1
SCHEMBL141522 0.84 JAK2 (0.80) JAK2PLA2G2AKLK7KDM4ECYP1A2
SCHEMBL178707 0.83 JAK2 (0.69) JAK2KDM4EMAPTNPC1LMNA
SCHEMBL140965 0.78 JAK2 (0.69) JAK2PLA2G2AKLK7KDM4ESMN1; SMN2
SCHEMBL141924 0.77 JAK2 (0.60) JAK2PLA2G2AKLK7KDM4ECYP1A2
SCHEMBL145362 0.76 JAK2 (0.66) JAK2PLA2G2AKDM4EALDH1A1
SCHEMBL142655 0.74 JAK2 (0.78) JAK2PLA2G2AKDM4EMAPTNPC1
SCHEMBL143862 0.74 JAK2 (1.00) JAK2PLA2G2AKLK7KDM4ELMNA
SCHEMBL142463 0.73 JAK2 (0.77) JAK2PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885PLA2G2A 4509/4885KLK7 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.